Full-Time

Migration Architect

Migration Architect

Veeva Systems

Veeva Systems

10,001+ employees

Cloud-based quality, regulatory, and claims management

No salary listed

Dublin, Ireland

Remote

EU/UK-based candidates; up to 20% travel within Europe.

Category
Consulting (1)
Required Skills
SharePoint
ETL
SAP Products
Salesforce
Oracle

Get referred to Veeva Systems

See people who can refer or advise you

Requirements
  • 8+ years of data and content migration experience within enterprise systems (e.g., Documentum, OpenText, Box, SharePoint, SAP, Salesforce, Oracle)
  • 5+ years of project leadership and customer-facing consulting experience, specifically managing the implementation of complex technical solutions in an enterprise software environment
  • Strong ability to communicate complex concepts to senior business and technical stakeholders
  • Familiarity with Life Sciences industry regulations (GxP, validation processes)
  • Proven ability to lead, mentor, and inspire cross-functional teams
  • Ability to travel up to 20% across Europe as needed
Responsibilities
  • Lead and deliver Vault R&D migration projects, ensuring smooth transitions from legacy systems to the Vault Platform
  • Own migration projectsend-to-end, from initial strategy through execution and validation
  • Advise customers through every stage of the ETL (Extract, Transform, Load) process, ensuring data quality and compliance
  • Coach and mentor Data Migration Specialists, fostering growth and consistency across teams. Contribute to internal knowledge sharing, helping evolve our migration frameworks and best practices
  • Support customer validation and verification activities to ensure readiness and compliance
  • Collaborate with engineering to refine and enhance migration tooling and automation processes
  • Support project scoping and estimation, bringing both technical depth and strategic insight
Desired Qualifications
  • Direct experience in the Pharmaceutical or Life Sciences industry
  • Functional knowledge of Clinical, Regulatory, Quality, or Safety business processes
  • Deep understanding of the migration verification and reconciliation process
  • Coding experience, particularly with Java or Python

Veeva Systems provides cloud-based software that helps consumer goods and chemical companies manage quality, regulatory compliance, and advertising claims. The platform works by connecting different departments—from the supply chain to marketing—to provide a single source of data that tracks a product's journey and ensures it meets safety standards. Unlike competitors that offer general business tools, Veeva specializes in navigating the highly complex regulations originally found in the life sciences sector and applies that specific expertise to other regulated industries. The company's goal is to help businesses bring safe, sustainable, and compliant products to market faster by providing end-to-end visibility and traceability.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

2007

Get referred to Veeva Systems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2027 revenue reached $882.9 million on June 3, 2026, beating estimates.
  • Copli became Veeva Falcon MLR on June 23, 2026, expanding AI monetization.
  • Veeva EHS launched June 25, 2026, adding a new Quality Cloud wedge.

What critics are saying

  • Salesforce CRM migration pressure remains explicit in Veeva's 2026 10-K.
  • Veeva Falcon AI invites scrutiny if outputs fail GxP review or misstate regulated content.
  • A major security breach would damage trust, trigger lawsuits, and stall renewals quickly.

What makes Veeva Systems unique

  • Veeva Vault CRM deepens lock-in across regulated life sciences workflows and data.
  • Veeva Falcon MLR automates compliant content review inside PromoMats, not a standalone tool.
  • UCB's June 2026 Safety Suite rollout shows enterprise-grade switching costs and implementation depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Parental leave

PTO

Free food

Health, dental, & vision insurance

Gym membership reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Jul 30th, 2026
Vulcan Value Partners buys Veeva Systems as life sciences software firm grows revenue 16%, EBIT 24%

Vulcan Value Partners added Veeva Systems to its All-Cap strategy in Q2 2026, describing the company as the dominant vertical market software system of record for the life sciences industry. The investment firm noted that Veeva's customers rely on its platform to run their entire business, from drug development and regulatory approval to manufacturing, selling, and marketing. Veeva grew revenue and EBIT by 16% and 24% respectively in 2025 and maintained strong momentum into 2026. Despite these results, the stock fell nearly 20% year-to-date through end-June, moving in sympathy with the broader application software sector. On 29 July 2026, Veeva shares closed at $207.91, giving it a market capitalisation of $33.77 billion. According to data, 62 hedge funds held Veeva at the end of Q1, down from 75 in the previous quarter.

IDDI
Jul 17th, 2026
IDDI joins Veeva CRO Partner Program to expand eClinical technology offerings for clinical trials.

IDDI joins Veeva CRO Partner Program to expand eClinical technology offerings for clinical trials. July 17, 2026. BRUSSELS; RALEIGH, N.C.; July. 16, 2026 - IDDI today announced it has joined the Veeva CRO Partner Program, further expanding its eClinical technology ecosystem to support sponsors running clinical trials of all sizes and complexities. As a leading provider of biometrics services, including biostatistics, data management, RTSM, and strategic consulting, IDDI is committed to helping sponsors select the technologies that best fit their protocol requirements and operational needs. Through this partnership, IDDI will expand the range of eClinical solutions available to its customers by adding Veeva Clinical Data applications, including Veeva EDC, Veeva DQS, Veeva eCOA, and Veeva RTSM. By combining scientific expertise with advanced technology solutions, IDDI helps sponsors build efficient, scalable clinical trial strategies that support high-quality data collection, streamlined study execution, and successful clinical outcomes. "Sponsors need the flexibility to build clinical technology ecosystems that support their unique study requirements," said Tara Kervin, Chief Operating Officer at IDDI. "By joining the Veeva CRO Partner Program, we are expanding our eClinical technology portfolio with Veeva's EDC, DQS, eCOA, and RTSM solutions. Together, we can better align technology with protocol design, giving sponsors greater choice while helping them execute studies more efficiently and confidently." The partnership reflects a shared commitment to providing life sciences organizations with modern, connected solutions that support efficient trial execution and enable teams to manage increasingly complex studies with confidence. About IDDI IDDI is a trusted clinical data science partner. With 35+ years of research-driven experience, IDDI Inc. combine therapeutic expertise, biostatistical leadership, and regulatory insight to mitigate risk from design to registration and beyond. IDDI Inc. deliver uncompromising excellence in biostatistics, strategic consulting, clinical data management, IDMCs, and supporting eClinical technologies, because when every data point represents a patient, perfection is the only option.

Yahoo Finance
Jul 2nd, 2026
Stifel maintains Buy rating on Veeva Systems with $230 price target after Copli acquisition

Stifel has reiterated its Buy rating and $230 price target on Veeva Systems following the company's acquisition of Copli, an agentic medical, legal and regulatory solutions firm. Veeva rebranded the acquisition as Veeva Falcon MLR, claiming the solution can eliminate 70% or more of manual MLR labour within five years. The system conducts compliance checks on promotional and medical materials against approved labels and local regulations. Separately, Veeva launched Veeva EHS on 25 June, a new environmental, health and safety application within its Veeva Quality Cloud. Veeva Systems delivers industry cloud solutions for life sciences, offering software, AI, data and consulting services.

PR Newswire
Jun 25th, 2026
Veeva launches EHS application for proactive risk management with AI-driven automation

Veeva Systems has announced Veeva EHS, a new environmental, health and safety application within Veeva Quality Cloud. The solution enables manufacturing and testing sites to identify, manage and mitigate operational and environmental risks whilst ensuring global compliance readiness. Veeva EHS integrates directly with Veeva QMS and Veeva Training, allowing safety events to automatically trigger quality deviations and assign targeted retraining. This eliminates duplicate data entry and streamlines workflows across the entire EHS process. The application provides real-time insights into leading risk indicators and uses intelligent automation to improve site efficiency. Planned for early adopter availability in August 2026, Veeva EHS represents a significant advancement in how organisations manage environmental, health and safety responsibilities through a unified platform.

Bio-IT World
Jun 24th, 2026
Veeva introduces new EHS application for proactive risk management and intelligent automation.

Veeva introduces new EHS application for proactive risk management and intelligent automation. June 24, 2026 Environmental, health, and safety solution is part of Veeva Quality Cloud and will deliver real-time insights and streamlined workflows PLEASANTON, CA - June 25, 2026 - Veeva Systems (NYSE: VEEV) today announced Veeva EHS, a new application in Veeva Quality Cloud for environmental, health, and safety. With Veeva EHS, manufacturing and testing sites can proactively identify, manage, and mitigate operational and environmental risks and ensure global compliance readiness. "A modern EHS solution that simplifies processes through unified data and a seamless user experience across the entire EHS workflow can significantly improve site efficiency," said Bobbie Grant, global senior EHS manager, Thermo Fisher Scientific. "It is exciting to see Veeva build an advanced solution that can not only maintain data integrity today but also provide the foundation for AI-driven capabilities that can further reduce risk over time." Veeva EHS will provide an intuitive way to report safety incidents on the spot and manage investigations from start to finish. Because it connects directly with Veeva QMS and Veeva Training, a safety event can automatically trigger a quality deviation and assign targeted retraining, eliminating duplicate data entry and ensuring compliance. "Delivering an advanced, automated approach to managing environmental, health, and safety processes, Veeva EHS will free up time for EHS teams and ensure quick and accurate execution," said Beth Tanner, vice president, Veeva EHS strategy. "Organizations replacing legacy EHS systems with a unified platform will gain real-time transparency into leading indicators of risk for more informed decisions and a proactive approach to prevention." Planned for early adopter availability in August 2026, Veeva EHS marks a significant step in how organizations manage environmental, health, and safety responsibilities with increased transparency and intelligent automation. About Veeva Systems Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Veeva Forward-Looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of its products and services. These statements are based on its current expectations. Actual results could differ materially from those provided in this release and Bio-IT World has no obligation to update such statements. There are numerous risks that have the potential to negatively impact its results, including the risks and uncertainties disclosed in its filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find here (a summary of risks which may impact its business can be found on pages 33 and 34), and in its subsequent SEC filings, which you can access at sec.gov.